Should I buy or sell Wave Life Sciences stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares. View WVE analyst ratings or view top-rated stocks .

What is Wave Life Sciences' stock price target for 2024?

6 Wall Street research analysts have issued 1 year price objectives for Wave Life Sciences' shares. Their WVE share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 30.1% from the stock's current price. View analysts price targets for WVE or view top-rated stocks among Wall Street analysts .

How have WVE shares performed in 2023?

Wave Life Sciences' stock was trading at $7.00 on January 1st, 2023. Since then, WVE shares have decreased by 18.7% and is now trading at $5.69. View the best growth stocks for 2023 here .

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024. View our WVE earnings forecast .

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Thursday, November, 9th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.21. The firm had revenue of $49.21 million for the quarter, compared to analysts' expectations of $28.81 million.

What ETF holds Wave Life Sciences' stock ?

iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com . Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD) , Exelixis (EXEL) , Sangamo Therapeutics (SGMO) , Sorrento Therapeutics (SRNE) , TherapeuticsMD (TXMD) , VBI Vaccines (VBIV) , Aduro Biotech (ADRO) , Cidara Therapeutics (CDTX) , CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN) .

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include M28 Capital Management LP (7.11%), 683 Capital Management LLC (5.91%), Kynam Capital Management LP (3.97%), Adage Capital Partners GP L.L.C. (3.82%), Primecap Management Co. CA (3.82%) and Laurion Capital Management LP (0.88%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP. View institutional ownership trends .

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Positive News SentimentPositive News

Wave Life Sciences Stock Price, News & Analysis (NASDAQ:WVE)

$5.51

+0.20 (+3.77%)

(As of 02:50 PM ET)

Compare

Today's Range: $5.27
▼
$5.69
50-Day Range: $5.12
▼
$6.02
52-Week Range: $3.15
▼
$7.12

Volume: 274,275 shs
Average Volume: 367,550 shs
Market Capitalization: $545.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.40

Wave Life Sciences MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 30.1% Upside
$7.40 Price Target
Short Interest: Bearish
3.51% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.58
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.60) to ($1.09) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

495th out of 948 stocks

Pharmaceutical Preparations Industry

235th out of 449 stocks

3.3

Analyst's Opinion

Consensus Rating
Wave Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.40, Wave Life Sciences has a forecasted upside of 30.1% from its current price of $5.69.
Amount of Analyst Coverage
Wave Life Sciences has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.51% of the outstanding shares of Wave Life Sciences have been sold short.
Short Interest Ratio / Days to Cover
Wave Life Sciences has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
Change versus previous month
Short interest in Wave Life Sciences has recently decreased by 3.06%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Wave Life Sciences does not currently pay a dividend.
Dividend Growth
Wave Life Sciences does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Wave Life Sciences has received a 77.37% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Wave Life Sciences is -0.58.

2.7

News and Social Media Coverage

News Sentiment
Wave Life Sciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Wave Life Sciences this week, compared to 1 article on an average week.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Wave Life Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.10% of the stock of Wave Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
72.91% of the stock of Wave Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Wave Life Sciences are expected to decrease in the coming year, from ($0.60) to ($1.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Wave Life Sciences is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Wave Life Sciences is -6.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Wave Life Sciences Stock (NASDAQ:WVE)

Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.

WVE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

WVE Stock News Headlines

November 22, 2023 | tmcnet.com

Wave Life Sciences to Present at 6?? Annual Evercore ISI HealthCONx Conference

November 22, 2023 | finance.yahoo.com

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

December 1, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: ARS Pharmaceuticals (SPRY), Wave Life Sciences (WVE) and AC Immune SA (ACIU)

November 11, 2023 | finance.yahoo.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2023 Earnings Call Transcript

November 11, 2023 | markets.businessinsider.com

Wave Life Sciences: Buy Rating Based on Potential Pipeline Success and Key Catalysts for 2024

November 11, 2023 | finance.yahoo.com

Analysts Just Made A Notable Upgrade To Their Wave Life Sciences Ltd. (NASDAQ:WVE) Forecasts

November 9, 2023 | morningstar.com

WAVE Life Sciences Ltd WVE

December 1, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 9, 2023 | finance.yahoo.com

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 8, 2023 | msn.com

Wave Life Sciences Q3 2023 Earnings Preview

November 3, 2023 | finance.yahoo.com

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

October 27, 2023 | fool.com

Wave Life Sciences (NASDAQ: WVE)

September 29, 2023 | finance.yahoo.com

Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?

September 28, 2023 | finance.yahoo.com

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

September 25, 2023 | finance.yahoo.com

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

September 18, 2023 | finance.yahoo.com

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

September 6, 2023 | finance.yahoo.com

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023 | finance.yahoo.com

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

August 23, 2023 | finance.yahoo.com

WAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three Months

August 10, 2023 | finance.yahoo.com

Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2023 Earnings Call Transcript

August 9, 2023 | markets.businessinsider.com

Truist Financial Sticks to Their Buy Rating for Wave Life Sciences (WVE)

August 8, 2023 | finance.yahoo.com

Analyst Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher

August 4, 2023 | markets.businessinsider.com

RBC Capital Sticks to Its Hold Rating for Wave Life Sciences (WVE)

August 4, 2023 | finance.yahoo.com

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 42% Price Boost Is Out Of Tune With Revenues

July 27, 2023 | finance.yahoo.com

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

July 6, 2023 | finance.yahoo.com

Wave Life Sciences (NASDAQ:WVE) shareholders have endured a 90% loss from investing in the stock five years ago

See More Headlines

Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:WVE
CUSIP: N/A
CIK: 1631574
Web: www.wavelifesciences.com
Phone: (656) 236-3388
Fax: 617-949-2901
Employees: 250
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.40
High Stock Price Target: $10.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +39.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-161,820,000.00
Net Margins: -99.39%
Pretax Margin: -99.39%
Return on Equity: N/A
Return on Assets: -40.29%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.59
Quick Ratio: 1.59

Sales & Book Value

Annual Sales: $3.65 million
Price / Sales: 144.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.41) per share
Price / Book: -12.95

Miscellaneous

Outstanding Shares: 99,050,000
Free Float: 68,248,000
Market Cap: $525.96 million
Optionable: Optionable
Beta: -1.08

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Paul B. Bolno M.B.A. (Age 49)
M.D., President, CEO & Director
Comp: $1.1M
Mr. Kyle B. Moran CFA (Age 52)
CFO & Principal Accounting Officer
Comp: $677.87k
Dr. Chandra Vargeese Ph.D. (Age 62)
CTO & Head of Platform Discovery Sciences
Comp: $710.05k
Kate Rausch
Head of Investor Relations
Ms. Linda Rockett J.D.
General Counsel
Dr. Christopher Francis Ph.D. (Age 45)
Senior VP of Corporate Development & Head of Emerging Areas
Comp: $493.13k
Ms. Daryn Lewis
Senior VP & Head of Human Resources
Dr. Sridhar Vaddeboina Ph.D.
Senior Vice President of Chemistry, Manufacturing & Controls
Ms. Anne-Marie Li-Kwai-Cheung
Chief Development Officer
Dr. Hsiu-Chiung Yang Ph.D.
Senior Vice President of Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

WVE Stock Analysis - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" WVE shares.
View WVE analyst ratings or view top-rated stocks.
What is Wave Life Sciences' stock price target for 2024?: 6 Wall Street research analysts have issued 1 year price objectives for Wave Life Sciences' shares. Their WVE share price targets range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 30.1% from the stock's current price.
View analysts price targets for WVE or view top-rated stocks among Wall Street analysts.
How have WVE shares performed in 2023?: Wave Life Sciences' stock was trading at $7.00 on January 1st, 2023. Since then, WVE shares have decreased by 18.7% and is now trading at $5.69.
View the best growth stocks for 2023 here.
When is Wave Life Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 27th 2024.
View our WVE earnings forecast.
How were Wave Life Sciences' earnings last quarter?: Wave Life Sciences Ltd. (NASDAQ:WVE) posted its quarterly earnings data on Thursday, November, 9th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.21. The firm had revenue of $49.21 million for the quarter, compared to analysts' expectations of $28.81 million.
What ETF holds Wave Life Sciences' stock ?: iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?: 17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Wave Life Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).
Who are Wave Life Sciences' major shareholders?: Wave Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include M28 Capital Management LP (7.11%), 683 Capital Management LLC (5.91%), Kynam Capital Management LP (3.97%), Adage Capital Partners GP L.L.C. (3.82%), Primecap Management Co. CA (3.82%) and Laurion Capital Management LP (0.88%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends.
How do I buy shares of Wave Life Sciences?: Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:WVE) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial